Alzheimer's disease is neuropathologically characterized by the accumulation of amyloid-b protein into senile plaques that are sites of chronic inflammation involving reactive microglia, astrocytes, and proinflammatory molecules, such as interleukin-1b and tumor necrosis factor-a. The human CCAAT/enhancerbinding protein (CEBP) delta (CEBPD) is known to be induced in many inflammation-related diseases. In Alzheimer's disease, this protein is responsive to amyloid-b and proinflammatory cytokines in astrocytes. However, the functional role of CEBPD in astrocytes remains largely unclear. In this study, we show that CEBPD is upregulated by interleukin-1b through the mitogen-activated protein kinase p38 (MAPKp38) signaling pathway and phosphorylated by glycogen synthase kinase (GSK)-3b at Ser167 in astrocytes. CEBPD in astrocytes is associated with microglia activation and migration in amyloid precursor protein transgenic mice (AppTg) mice. We further identified that the monocyte chemotactic protein-1, a chemoattractive factor, and migration factors matrix metalloproteinase-1 and -3 are responsive to GSK3b-mediated CEBPD Ser167 phosphorylation. Our results revealed the novel regulation of LiCl on astrocytes and that GSK3b-mediated CEBPD phosphorylation in astrocytes plays an important role in the activation of microglia.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disease that occurs predominantly in elderly people and leads to behavioral changes. Two types of monocyte-macrophage cells, including parenchymal microglial cells and blood-borne monocytes, have been suggested to exist in brain tissue (Guillemin and Brew, 2004; Minagar et al., 2002) . Microglia/macrophages are the principal immune cells in the central nervous system (CNS), are concomitant with inflammatory brain disease, and play a significant role in host defense against invading micro-organisms. Astrocytes are primary supportive cells in the CNS and are believed to play an essential role in neuronal survival, function, and neurogenesis (Hazell, 2002; Nedergaard, 1994; Pfrieger and Barres, 1997; Song et al., 2002) . Astrocytes generate a response to brain injury through the production of growth factors that can further promote microglial growth and activation or modulate their cytotoxic activity (Ji et al., 1996; Riccio et al., 1999) . Although microglia/macrophages and astrocytes have been suggested to play a vital role in AD pathogenesis, the regulation of the crosstalk between microglia and astrocytes have not been fully investigated.
Glycogen synthase kinase (GSK)-3 is a highly conserved serine/ threonine protein kinase and is ubiquitously expressed in all eukaryotes. GSK3 acts as a downstream regulatory switch that responds to Wnt, growth factors, insulin, hedgehog pathways, and G-proteinecoupled receptors; in addition, GSK3 is involved in many processes, including cytoskeletal organization, cell cycle regulation, proliferation, and apoptosis. Mammalian cells have a and b GSK3 isoforms. GSK3b has been shown to favor previous phosphorylation of its substrate before it phosphorylates the substrate (Cohen and Frame, 2001 ). GSK3b plays an important role in the regulation of synaptic plasticity, cell survival, and circadian rhythms in the mature CNS. Although the activation of GSK3b was observed in inflamed astrocytes (Beurel and Jope, 2009; Kim et al., 2007) , little is known about the details of GSK3b biology in astrocytes in neuroinflammatory conditions.
CCAAT/enhancer-binding protein (CEBP) delta (CEBPD) is a member of the CCAAT/enhancer-binding protein (C/EBP) family and serves as a transcription factor for tissue differentiation, metabolism, and immune responses (Ishii et al., 2005; Lai et al., 2008; Ramji and Foka, 2002; Takeji et al., 2004) . CEBPD is expressed at relatively low levels in physiological conditions and is upregulated by a variety of extracellular stimuli, such as interleukin (IL)-6 (Sanford and DeWille, 2005) , lipopolysaccharide (Liu et al., 2003) , IL-1b (Ko et al., 2012; Svotelis et al., 2005) , tumor necrosis factor (TNF)-a (Cardinaux et al., 2000) and interferon-g (Tengku-Muhammad et al., 2000) . Moreover, CEBPD also can induce expressions of cytokines including IL-6, IL-1b, and TNF-a (Akira et al., 1990; Kinoshita et al., 1992; Poli, 1998) . In AD, phagocytic microglia travel to the site of injury in the inflamed brain to engulf the offending material and secrete proinflammatory factors that promote cell proliferation. Activated phagocytic microglia also interact with astrocytes and neural cells to fight off infections as quickly as possible with minimal damage to healthy brain cells. Elevated CEBPD expression was observed in the astrocytes of AD patients (Li et al., 2004) . A recent study showed that astrocytic CEBPD responds to IL-1b and contributes in attenuating macrophage-mediated phagocytosis of damaged neurons through pentraxin-3 (Ko et al., 2012) .
Posttranslational modifications play an important role in precisely controlling protein function. CEBPD is an acetyl-and sumoconjugated protein (Wang et al., 2006) . We provided models to illustrate that CEBPD can serve as a positive or negative regulator through its various posttranslational modifications in transcriptional regulation (Lai et al., 2008; Wang et al., 2006 Wang et al., , 2008 . In this study, we demonstrated that MAPKp38 mediated IL-1beinduced CEBPD gene expression and GSK3b modified CEBPD at Ser167. Importantly, the conditioned medium harvested from astrocytes expressing CEBPDS167A and LiCl-treated cells show similar attenuation of microglia/macrophages migration. We determined that the phosphorylation of CEBPD at Ser167 participated in the transcription of monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-1 (MMP-1), and matrix metalloproteinase-3 (MMP-3) genes is altered by a direct binding to their promoter regions in astrocytes.
Methods

Materials
An anti-aetubulin antibody was purchased from Sigma (St Louis, MO, USA). An anti-induction of brown adipocytes 1 (Iba1) antibody was purchased from Wako (Osaka, Japan). Anti-CEBPD, -glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and -cyclooxygenase 1 (COX-1) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phophoeGSK3a/b (S21/S9) and anti-phosphoep38 were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-phophoeCEBPD S167 and T171 were produced by GeneTex (Irvine, CA, USA). The TRIzol RNA extraction reagent, Lipofectamine 2000, Dulbeco's modified Eagle's medium (DMEM), SuperScript III, anti-glial fibrillary acidic protein (GFAP) antibody, and Opti-MEM medium were obtained from Invitrogen (Carlsbad, CA, USA). All oligonucleotides were synthesized by MDBio Inc (Taipei, Taiwan). Fetal bovine serum was purchased from HyClone Laboratories (Logan, UT, USA). Cebpddeficient mice were obtained from Dr E. Sterneck (Sterneck et al., 1998) .
Cell culture
U373MG (human glioblastoma-astrocytoma cell line) cells were cultured in DMEM, containing 10% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL penicillin. BV-2 cells (murine microglial cell line, immortalized by infection with with v-raf/c-myc recombinant retrovirus) (Blasi et al., 1990) were grown in DMEM with 5% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL penicillin. For inducible expression of CEBPD wild type and mutants, the pMT/HA-CEBPD WT, pMT/HA-CEBPD S167A and pMT/ HA-CEBPD T171A constructs were introduced into U373MG cells and stable clones were selected using G418.
In vitro calf intestinal alkaline phosphatase assay
For in vitro dephosphorylation of CEBPD, the cell extracts were combined with 10 U of alkaline phosphatase (New England Biolabs, Beverly, MA, USA) containing 50 mM Tris (pH 7.9), 100 mM NaCl, 10 mM MgCl 2 , and 1 mM dithiothreitol (DTT) in calf intestinal alkaline phosphatase buffer and then the mixture was incubated at 37 C for 1 hour.
In vitro kinase assay
For the in vitro phosphorylation analysis, the wild type His-taggedeCEBPD and various point mutations of CEBPD were purified from Escherichia coli BL21 (DE3). These CEBPD proteins and active GSK3b or casein kinase I (CKI) were used to examine CEBPD phosphorylation in vitro. Each reaction (20 mL) contained 1 mg of purified CEBPD, 0.015 U of active GSK3b or CKI, 2 mCi of [g-32 P] adenosine triphosphate (GE Healthcare) or 1 mM ATP (New England Biolabs) and 2 mL of 10X kinase buffer containing 500 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4), 10 mM MgCl 2 , 1 mM ethylene glycol tetraacetic acid (EGTA), and 1 mM DTT. The phosphorylation reactions were incubated at 37 C for 15 minutes. After the incubation, half of the reaction was added to 10 mL of 2X electrophoresis sample buffer, which was then heated to 95 C for 5 minutes. Proteins in the mixtures were immediately separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Plasmid transfection and reporter gene assay
Cells were replated 24 hours before transfection at an optimal density in 2 mL of fresh culture medium in a 6-well plastic plate. They were then transfected with plasmids using Lipofectamine 2000 according to the manufacturer's instructions. The total amount of DNA for each experiment was matched with the empty vector. The Opti-MEM media were changed to conditional medium and incubated for 15 hours. The promoter fragments of MCP-1 (approximately À734 to 37), MMP1 (approximately À600 to 71) and MMP3 (approximately À600 to 65) were cloned using polymerase chain reaction (PCR) of genomic DNA from HeLa cells and inserted into the promoterless pGL2-Basic vector (Promega, Madison, WI). After transfection, the luciferase activities in cell lysates were measured using the luciferase assay system as per the manufacturer's instructions (Promega).
Reverse transcription PCR
Total RNA was isolated using the TRIzol RNA extraction kit and 1 mg of RNA was subjected to reverse transcription (RT)-PCR using SuperScript III. Specific primers used for the RT-PCR analysis were: for CEBPD, 5 0 -AGCGCAACAACATCGCCGTG-3 0 and 5 0 -GTCGGGTCT-GAGGTATGGGTC-3 0 ; for GAPDH, 5 0 -CCATCACCATCTTCCAGGAG-3 0 and 5 0 -CCTGCTTCACCACCTTCTTG-3 0 ; for monocyte chemotactic protein (MCP)-1, 5 0 -ATAGCAGCCACCTTCATTCC-3 0 and 5 0 -AGCTTC-TTTGGGACACTTGC-3 0 ; for matrix metalloproteinase (MMP)-1, 5 0 -CTGCTTACGAATTTGCCGACAGA-3 0 and 5 0 -GTTCTAGGGAAGCCAAA-GGAGCTG-3 0 ; for MMP3, 5 0 -AGCAAGGACCTCGTTTTCATT-3 0 and 5 0 -GTCAATCCCTGGAAAGTCTTCA-3 0 . The PCR products were separated using 1% agarose gel electrophoresis and visualized using ethidium bromide staining.
Western blot analysis
For Western blot analysis, cells were lysed with modified radio immunoprecipitation assay (RIPA) buffer, including 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM DTT, 10 mM NaF, 1 mM phenylmethanesulfonyl fluoride (PMSF), aprotinin 1 mg/mL, leupeptin 1 mg/mL, and 1 mM Na 3 VO 4 . Lysates were resolved on a sodium dodecyl sulfate-containing 10% polyacrylamide gel, transferred to polyvinylidene difluoride nylon membrane, and probed with specific antibodies at 4 C overnight. Specific bands were detected using a horseradish peroxidase-conjugated antibody and revealed using an enhanced chemiluminescence Western blot system from Pierce (Rockford, IL, USA).
Immunoprecipitation
U373MG cells were washed with phosphate buffered saline (PBS). Lysate was prepared using modified RIPA buffer. The supernatant was added with anti-CEBPD antibody at 4 C for 1 hour. Protein-A/G agarose beads were added to the lysate, and the mixture was incubated during shaking at 4 C for 1 hour. The beads were collected using centrifugation and washed 3 times with modified RIPA buffer. Proteins binding to the beads were eluted by adding 2X electrophoresis sample buffer and followed by Western blot analysis.
Cell migration assays
For the wound-healing assay, BV-2 cells (5 Â10 5 ) were cultured in 3.5-cm dishes and wounded with a sterile plastic tip, producing scars, then incubated with different conditioned medium. Cell migration into the open space was monitored using microscopy. Photomicrographs were taken immediately and at 6 and 12 hours after wounding. Relative migration activity of cells was analyzed using WimScratch software (Wimasis, Munich, Germany). For transwell migration, transwell filters (with 8-mm pore size; Corning Costar, Bodenheim, Germany) containing BV-2 cells (10 5 ) were put into a 24-well plate. Cells were allowed to migrate into the lower chamber containing 300 mL conditioned medium for 3 hours and then transwell inserts were removed for analysis. Cells remaining on the upper surface of the insert were carefully aspirated, leaving those that had migrated to the surface underneath in place. The insert was then transferred to a clean well containing 225 mL of nonenzymatic cell dissociation solution (Sigma) and incubated for 30 minutes at 37 C. Cells were counted using phase-contrast microscopy.
Lentiviral knockdown assay
Virus was produced from Phoenix cells by cotransfection of the various small hairpin RNA (shRNA) expression vectors in combination with pMD2.G and psPAX2. After determining the viral infection efficiency, 10 multiplicity of infection of lentivirus containing shb-galactosidase (shLacZ) or shCEBPD were used to infect U373MG cells for 96 hours. In all lentiviral experiments, medium containing uninfected viruses was removed before conducting further assays. The shRNA sequences in lentiviral expression vectors were: shb-galactosidase, 5 0 -CCGGTGTTCGCATTATCCGAAC-CATCTCGAGATGGTTCGGATAATGCGAACATTTTTG-3 0 and shCEBPD, 5 0 -CCGGGCCGACCTCTTCAACAGCAATCTCGAGATTGCTGTTGAAGAG-GTCGGCTTTTT-3 0 . The lentiviral knockdown expression vectors were obtained from the National RNAi Core Facility located at the Genomic Research Center of Institute of Molecular Biology, Academia Sinica (Taiwan).
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay was carried out essentially as described by Wang et al. (2006) . Briefly, U373MG cells were treated with 1% formaldehyde for 15 minutes. The crosslinked chromatin was then prepared and sonicated to an average size of 500 base pair. The DNA fragments were immunoprecipitated with antibodies specific for CEBPD, phosphoCEBPDS167, or control rabbit immunoglobulin G at 4 C overnight. After reversal of the cross-linking, the immunoprecipitated chromatin was amplified using primers related to the specific regions of the target genes' genomic locus. The primers were: for MCP-1 genomic locus, 5 0 -CTGGCATTTCTTCTGCAGCACTACATGC-3 0 and 5 0 -AGCCAGGAAG-GAGCTCTCAAGCTTTG-3 0 ; for MMP1 genomic locus, 5 0 -CCACTGTT-TACATGGCAGAGTGTGTCTC-3 0 and 5 0 -CAGAAAGCCAGAGGCTGTC-TGACTCATG-3 0 ; for MMP3 genomic locus, 5 0 -GCTCCAGTTTT-CTCCTCTACCAAGAC-3 0 and 5 0 -GCTTTCATCCAAATGGCAGCAGGAC-3 0 . The amplified DNA products were resolved using agarose gel electrophoresis and confirmed using sequencing.
Immunofluorescence analysis
Brain tissue dissections were postfixed in 4% buffered paraformaldehyde for 24e36 hours, cryoprotected, sectioned at 10 mm on a freezing microtome, and stored at À20 C in 33% glycerin, 33% glycerol, and 33% phosphate buffer (pH 7.4) solutions. After permeabilizing with 0.4% Triton X-100 and blocking in 3% bovine serum albumin, the slices were incubated overnight in first antibody. After 3 washes in 0.2% Triton X-100/PBS, slices were incubated with secondary antibody for 1 hour at room temperature. Slices were thoroughly washed in 0.2% Triton X-100/PBS, counterstained and mounted on glass slides with ProLong Gold antifade reagent with 4 0 ,6-diamidino-2-phenylindole (Invitrogen) for immunofluorescence microscopy analysis.
Results
CEBPD is highly expressed in the astrocytes of AppTg mice and influences the activation of microglia
Elevated CEBPD expression has been found in astrocytes of AD patients (Li et al., 2004) . Although the level of mouse CEBPD (Cebpd) is increased in the brain of AppTg mice (Ko et al., 2012) , the specificity of cells expressing Cebpd in these mice remains unclear. Similar to AD patients, an immunofluorescence assay showed that the activation of Cebpd was mainly observed in the astrocytes of AppTg mice (Fig. 1A) . To further clarify the biological function of CEBPD in AD pathogenesis, we crossed AppTg mice with Cebpddeficient (Cebpd À/À ) mice. We found that the number of activated astrocytes was attenuated in the areas surrounding amyloid-b (Ab) plaques in AppTg/Cebpd À/À mice (Fig. 1B , lower panel) compared with AppTg mice (Fig. 1B, upper panel) according to GFAP staining. Moreover, the microglia activation was also decreased in in AppTg/ Cebpd À/À mice (Fig. 1C , lower panel) compared with AppTg mice (Fig. 1C, upper panel) according to Iba1 staining. The GFAP and Iba1 immunofluorescent staining intensity was quantitated in brain slices of AppTg or AppTg/Cebpd À/À mice (Fig. 1D) . These results implied that astrocytic CEBPD might contribute to microglia activation and migration. In addition, the loss of Cebpd in AppTg mice showed a significant attenuation in the GFAP signal, suggesting that Cebpd could also play an important role in astrogliosis of AD pathogenesis.
Proinflammatory cytokines can induce CEBPD phosphorylation in astrocytes
We have reported that IL-1b and TNF-a can induce CEBPD gene expression (Ko et al., 2012) , though the specific mechanism of action remains unknown. In addition, a mobility shift pattern was observed after 3 hours of IL-1b and TNF-a exposure ( Fig. 2A) . To determine whether this mobility shift pattern results from a modification of protein phosphorylation, we pretreated cell lysates with calf intestinal alkaline phosphatase and conducted a Western blot analysis. An attenuated mobility shift pattern suggests that IL1b and TNF-a induce the phosphorylation of CEBPD in astrocytes ( Fig. 2B ; compare lane 2 with 3 and lane 5 with 6).
The activation of GSK3b and MAPKp38 is altered after TNF-a and IL-1b exposure in astrocytes (Rojo et al., 2008) . We tested the effect of GSK3b and MAPKp38 on the expression of CEBPD using LiCl, a GSK3b inhibitor, and SB203580, a MAPKp38 inhibitor, respectively. As shown in Fig. 3A , LiCl, but not SB203580, specifically inhibited the phosphorylation of CEBPD induced by IL-1b or TNF-a (Fig. 3A and Supplementary Fig. 1 ). This result suggests that CEBPD is a GSK3b substrate mediated by IL-1b and TNF-a in astrocytes. To identify the GSK3b-targeted Ser/Thr residues on the CEBPD protein, various recombinant His/CEBPD proteins were produced for in vitro kinase assay (Fig. 3B) . The mutations of CEBPD/S167A and CEBPD/ T171A showed an attenuated GSK3b kinase effect (Fig. 3C) . To investigate the in vivo phosphorylation of CEBPDS167 and CEBPDT171 in astrocytes, 2 antibodies that specifically recognize CEBPDS167 and CEBPDT171 were generated. After using Western blot analysis to assess these antibodies with in vitro GSK3b-phosphorylated His/CEBPD proteins ( Supplementary Fig. 2 ), we examined the phosphorylation of CEBPD in astrocytes treated with IL-1b. Western blot and immunoprecipitation analysis showed that phosphorylated CEBPDS167 is detectable after IL-1b treatment (Fig. 4) . However, phosphorylated CEBPDT171 showed a consistent phosphorylation pattern, suggesting that residue Ter171 is a constitutive phosphorylation site; thus, CEBPD normally exists as a hypophosphorylated protein in astrocytes.
GSK3b-mediated phosphorylation of CEBPD at Ser167 contributes to the migration and chemoattractant detection of microglia/macrophages
We sought to determine whether phosphorylated CEBPDS167 and CEBPDT171 in astrocytes play a functional role in the migration and activation of microglia/macrophages, so we generated 2 other zinc-induced stable clones of CEBPD, S167A and T171A, in astrocytes (Fig. 5A) . First, we assessed changes in the conditional medium collected from IL-1betreated astrocytes with or without LiCl treatment. Three types of macrophages, BV-2 microglia, THP-1 macrophages (differentiated using phorbol-12-myristate-13-acetate [PMA] ) and primary bone marrow derived macrophage (differentiated by macrophage colony-stimulating factor [M-CSF]) were used to assess the regulation of astrocytes. In a wound-healing assay, the conditional medium from LiCl-treated U373MG cells inhibited IL-1beinduced mobility of BV-2 microglia (Fig. 5B) . The conditional medium from CEBPD-overexpressed U373MG cells promoted the mobility of BV-2 microglia and primary macrophages; however, this phenomenon was attenuated in BV-2 microglia and primary macrophages cultured with conditional medium from CEBPDS167A-or CEBPDT171A-overexpressed U373MG cells (Fig. 5D and Supplementary Fig. 3A ). These results suggest that GSK3-mediated phosphorylation of CEBPD is important in the migration of microglia/macrophages. We next tested whether astrocytic CEBPD affects the chemoattraction of microglia/ macrophages. Using a transwell assay, we determined that the chemoattraction of BV-2 microglia was increased when cultured with conditioned medium from IL-1b-treated U373MG cells (Fig. 5C) . Importantly, the conditional medium from U373MG cells overexpressing CEBPDS167A or CEBPDT171A showed an attenuated effect in BV-2 microglia and THP-1 macrophages when compared with the conditioned medium from U373MG cells overexpressing CEBPD ( Fig. 5E and Supplementary Fig. 3B ). These data indicate that certain secretory factors involved in promoting cell migration were attenuated in the conditioned medium of CEBPDS167A and CEBPDT171A-overexpressed U373MG cells. To explore the potent astrocytic CEBPD downstream targets that control cell migration and chemoattraction, we assessed the global profiling of CEBPD-responsive genes in U373MG cells (Ko et al., 2012) . Several factors involved in chemoattraction and cell migration, including MCP-1, MMP1 and MMP3, were identified. Next, we examined whether these genes were regulated by IL-1b and CEBPD in astrocytes. After IL-1b exposure, the knockdown of CEBPD attenuated IL-1b-induced MCP-1, MMP1, and MMP3 transcripts (Fig. 6A) . A reporter assay was conducted using the cotransfection of CEBPD expression vectors with various reporters. This assay showed that the phosphorylation mutations CEBPDS167A and CEBPDT171A blocked the CEBPD-induced reporter activity (Fig. 6B) . Finally, an in vivo DNA binding assay was conducted to determine whether CEBPD binds to the promoter region of the identified genes. As shown in Fig. 6C , IL-b induced the binding of CEBPD to the promoter regions of MCP-1, MMP1, and MMP3 genes. Importantly, the phosphorylation of CEBPD on Ser167 produced a similar effect.
Discussion
In postmortem AD tissue, activated astrocytes were closely associated with amyloid plaques in the molecular layer of the cerebral cortex. It is known that astrocytes can be activated by Ab, which indicates a correlation between this protein and subsequent alterations in astrocyte function. Activation of CEBPD is observed in many inflammatory diseases, indicating that it is a common factor in inflammatory environments and might play a critical role in the pathogenesis of neuroinflammation. In this study, we found that Cebpd was highly expressed in activated astrocytes of AppTg mice. These data are similar to a previous report in human patient specimens (Li et al., 2004) . Moreover, the loss of Cebpd in AppTg mice produced significant attenuation of GFAP and Iba1 signals, suggesting that Cebpd plays an important role in astrocyte and microglial activation. However, it remains to be examined whether the loss of Cebpd alters Ab plaque deposition. After inducing CEBPD expression with IL-1b in astrocytes, we identified that GSK3b phosphorylates Ser167 of CEBPD; furthermore, the phosphorylation of astrocytic CEBPD contributes to the activation and migration of microglia/ macrophages. This novel finding highlights the importance of CEBPD in activated astrocytes and neuroinflammatory diseases.
Different from neurons, astrocytic CEBPD is phosphorylated by GSK3b and consequently activates the expression of MCP-1, MMP3, and MMP1 by binding to their promoter regions. Previously, we demonstrated that epidermal growth factor can induce CEBPD transcriptional activation through the MAPKp38/cAMP response element-binding protein pathway in A431 cells (Wang et al., 2005) . CEBPD was suggested to be a MAPKp38 substrate and was shown to interact with MAPKp38 using in vitro kinase and binding assays, respectively (Svotelis et al., 2005) . Our in vitro kinase assay showed that recombinant MAPKp38 protein phosphorylated CEBPD but not CEBPDS167A and CEBPDT171A mutations (Supplementary Fig. 4A ). However, treatment with the GSK3b inhibitor LiCl, but not the MAPKp38 inhibitor SB203580, shifted the pattern of IL-1beinduced CEBPD phosphorylation in U373MG cells (Fig. 3A ; compare lane 3 with 4). Interestingly, SB203580 treatment showed a coincident result of attenuating CEBPD protein expression as in A431 cells (Wang et al., 2005) . These results suggest that MAPKp38 plays a role in regulating CEBPD transcription, but not the posttranslational modification of CEBPD, in a cell type-dependent manner.
In addition to the IL-1be and TNF-aeinduced phosphorylation of CEBPDS167 in astrocytes, our preliminary results show that EGF also induces phosphorylation of CEBPD at the same position in A431 cells (Supplementary Fig. 5A ; compare lane 3 with 7). Furthermore, various gel-retarded patterns were observed in A431 cells responding to EGF treatment, similar to the phenomenon of hypoand hyperphosphorylation of retinoblastoma tumor suppressor protein ( Supplementary Fig. 5B) . Briefly, the EGF-induced phosphorylation of CEBPD (Supplementary Fig. 5B ; compare lane 3 with lane 1) was attenuated when the lysate was treated with a phosphatase (Supplementary Fig. 5B ; compare lane 4 with lane 3). CEBPD was observed at a lower position in phosphatase-treated lysates without EGF treatment (Supplementary Fig. 5B ; compare lane 2 with lane 1). These observations suggest that CEBPD is constitutively phosphorylated in the absence of EGF and rapidly hyperphosphorylated when stimulated by EGF. Although our current results suggest that the phosphorylation of CEBPDS167 is important for regulating MCP-1, MMP1, and MMP3, and consequently affects the recruitment of microglia/macrophages, we cannot rule out that other kinases, such as casein kinase I, regulate CEBPD at other residues in response to IL-1b and TNF-a in astrocytes.
In mammals, GSK3a and b are widely expressed at the RNA and protein levels, although some tissues show preferential expression of one of the isoforms. GSK3a and b are expressed in astrocytes.
GSK3b has been suggested to play a more important role than GSK3a in the nervous system (Hur and Zhou, 2010) . Although GSK3b was proven to regulate pathogenic mechanisms of AD and Parkinson's disease (Bhat and Budd, 2002; Nagao and Hayashi, 2009) , our current evidence cannot rule out the possibility that CEBPDS167 is a GSK3a substrate. However, additional experiments are needed to clarify the involvement of GSK3a because LiCl inhibits GSK3a and b activity. Some GSK3 substrates do not require a specific sequence, but rather phosphorylation by a priming kinase on a Ser or Thr residue phosphorylated at the fourth amino acid. This priming facilitates the phosphorylation of a Ser or Thr residue on the first amino acid by GSK3. Although this priming phosphorylation has been suggested to be a feature on GSK3b-phosphorylated substrates (Cohen and Frame, 2001; Jope and Johnson, 2004) , increased evidence shows that GSK3b can phosphorylate substrates in a priming-independent manner (Cho and Johnson, 2003; Doble and Woodgett, 2003) . In this study, GSK3b can phosphorylate Ser167 and Thr171 of CEBPD in an in vitro kinase assay. After the treatment of IL-1b, GSK3b activity is attenuated between 0 and 3 hours (Fig. 3A) . This activity matches the phosphorylation state of CEBPDS167 but not CEBPDT171 (Fig. 4A) . We then questioned whether the phosphorylation of Thr171 is an essential prime position for the further phosphorylation of Ser167, whether the phosphorylation of Ser167 and Thr171 by GSK3b can be independent, and whether CEBPDT171 is phosphorylated by other constitutively activated kinases, such as CKI. These issues need to be further investigated to determine their effects on the communication of microglia/macrophages and astrocytes.
MCP-1, a predominant chemoattractant, causes the migration and activation of microglia and macrophages (McManus et al., with a zinc-inducible CEBPD expression vector were exposed to 100 mM ZnSO 4 and wild type or mutant HA-tagged CEBPD protein expression was analyzed using Western blot. (B) and (D) Wound-healing migration assays were performed with BV-2 cells. Conditional medium from drug treatments or different CEBPD-overexpressed stable clones in U373MG cells exposed to interleukin (IL)-1b was added to the BV-2 cells. Photomicrographs were taken at the indicated time points. One representative experiment is shown and similar results were obtained in 3 independent cultures. (C) and (E) An in vitro chemotaxis assay with 8-mm transwell filter cultures was completed. Conditional medium from drug treatments or different CEBPD-overexpressed stable clones in U373MG cells after IL-1b treatment were put in a 24-well plate, and BV-2 cells were added to the transwell inserts. Transwell inserts were removed after 3 hours, and cells crossing the insert membrane were counted. Data represent the mean AE standard error of the mean of 3 independent cell cultures analyzed in triplicate wells (* p < 0.05, ** p < 0.01, Student t test). Abbreviations: C, control; CD, CEBPD wild type; S167A, CEBPD S167A; T171A, CEBPD T171A; HA, hemagglutinin. 2000). Macrophages secrete proinflammatory cytokines that can be neurotoxic at the sites of inflammation (Kaul et al., 2001; Persidsky and Gendelman, 2003) . MCP-1 is primarily secreted by monocytes, macrophages, and dendritic cells. Previous reports showed that MCP-1 can be produced after Ab treatment in a human U373MG astrocyte cell line (Prat et al., 2000) and might be linked to the maturation or degradation of senile plaques (Hurwitz et al., 1995; Ishizuka et al., 1997; Madrigal et al., 2009) . Here, we demonstrated that a novel IL-1b/GSK3b/pCEBPDS167 pathway activates MCP-1 expression in astrocytes. These findings also provide evidence to explain why the conditioned medium harvested from U373MG cells expressing CEBPD promoted the migration and activation of microglia/macrophages. MMPs comprise a family of proteolytic enzymes that are involved in the remodeling of the extracellular matrix in many tissues. They have been implicated in the degradation of vascular basement membranes thereby facilitating leukocyte migration into inflammatory sites. A growing amount of evidence suggests that MMPs might play an important role in the pathogenesis of AD (Gottschall and Deb, 1996) . Microglia and astrocytes have been shown to synthesize and secrete a wide range of MMP's, including MMP1, MMP2, and MMP3, after activation by Ab peptide treatment in vitro. MMP1, MMP3, and matrix metallopeptidase 9 are elevated in AD patients; however, the underlying mechanism for this finding is unknown (Leake et al., 2000; Lorenzl et al., 2003) . In this study, we found that MMP1 and MMP3 were elevated through a CEBPD-dependent pathway after IL-1b treatment in astrocytes.
In addition to MCP-1, as already mentioned, CEBPD was suggested to be involved in the transcriptional activation of IL-6, IL-1b, and TNF-a genes in various cell types. In astrocytes, we show that IL-1b induces the binding of CEBPD to promoters of its downstream genes. It implies a potent positive feedback regulation between CEBPD and proinflammatory cytokines IL-6, IL-1b, and TNF-a in astrocytes. However, the detailed mechanism of CEBPD-mediated gene regulation of these inflammatory cytokines remains to be investigated. Six members have been identified in mammalian cells, including CEBP alpha, CEBP beta, CEBPD, CEBP epsilon, CEBP gamma, and CEBP zeta. All CEBPs consist of a canonical basic domain and a C-terminal leucine zipper domain. The basic region binds to specific CCAAT motifs located in CEBP's targeted gene promoter, whereas the leucine zipper domain is responsible for heterodimer/homodimer formation between various CEBP , and MMP3 transcripts. Reverse transcription polymerase chain reaction assays were performed with total RNA harvested from U373MG cells transfected with shb-galactosidase (shLacZ) or shCEBPD after IL-1b treatment. (B) Inhibition of CEBPD phosphorylation decreases its transcriptional activity. The reporter vector carrying the MMP1, MMP3, or MCP1 promoter was cotransfected with the indicated expression vectors in U373MG cells. After 12 hours, the cells were treated with IL-1b for 3 hours and then the cell lysates were harvested for a luciferase assay (* p < 0.05, ** p < 0.01, *** p < 0.001, Student t test). (C) Phosphorylated CEBPD bound to its downstream target genes after IL-1b treatment. Chromatin from U373MG cells was immunoprecipitated (IP) with specific antibodies, including a control immunoglobulin G (IgG), CEBPD, or pCEBPD (S167) after 3 hours of IL-1b treatment. The precipitated DNA was amplified using specific primers for the MCP1, MMP1, or MMP3 promoter regions. Abbreviation: sh, small hairpin.
members (Ramji and Foka, 2002) . Actually, CEBP beta is also induced by IL-1b through the MAPKp38 pathway in astrocytes (Maranto et al., 2011) . However, the details and consequences related to interactions of CEBPD and other C/EBP family members in astrocytes still needs to be further investigated.
In response to damage, astrocytes can be activated. In addition, they are resistant to death receptor-induced apoptosis, which indicates that they are well equipped to survive inflammatory insults. The activation of astrocytes can be characterized by several features. First, the most commonly used marker of activated astrocytes is their upregulation of intermediate filaments (GFAP, vimentin, and to some extent, nestin) coincident with cellular hypertrophy and cell proliferation. Second, activated astrocytes are likely to increase their expression of cytokines, chemokines, and extracellular matrix components (Sofroniew, 2009) . Astrogliosis involves changes in the molecular expression and morphology of astrocytes. In severe cases, astrogliosis can lead to scar formation. Reactive astrogliosis consists of a spectrum of changes that occur in response to all forms and severities of CNS injury and diseases (Correa-Cerro and Mandell, 2007; Maragakis and Rothstein, 2006; Pekny and Nilsson, 2005) . Scarring astrocytes are considered to be a major impediment to the regeneration of damaged axons and reactive gliosis is regarded as being detrimental to nervous tissue repair and functional restoration (Kiyota et al., 2009; Potts and Leech, 2005; Rodriguez et al., 2009) . Therefore, molecular dissection of reactive astrogliosis is imperative for the development of novel therapeutic strategies. In our preliminary results, we found that GFAP was induced by CEBPD-overexpressing astrocytes (Ju-Ming Wang, unpublished results). The role of CEBPD in reactive astrogliosis should be further investigated.
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